DIRS.INFO The most relevant business & tech news

☆ Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
▼ + stars: | 2024-05-07 | by ( Eduardo Munoz | ) www.cnbc.com time to read: +3 min

A highly popular group of weight loss and diabetes drugs is still hard to find in the U.S. The dominant manufacturers of those treatments, Eli Lilly and Novo Nordisk , are making progress toward changing that. Patients using current autoinjectors for weight loss and diabetes drugs go through four different pens per month. Eli Lilly expects supply for Zepbound, Mounjaro and other incretin drugs to remain "quite tight" in the near- to mid-term as demand remains high, Ashkenazi said. On the day Eli Lilly reported earnings, shares of the company jumped more than 5% on the raised guidance and supply updates.

Persons: Eli Lilly, Anat Ashkenazi, There's, Ashkenazi, David Ricks, —, Lilly, Chris Schott Organizations: U.S, Novo Nordisk, Nexus Pharmaceuticals, JPMorgan Locations: North Carolina, Indiana, Ireland, Germany, Europe, U.S

☆ Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentum
▼ + stars: | 2024-04-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. Based on that calculation, earnings will be lower by about 13 cents per share, he said, in research published last Tuesday. "Strong demand for Mounjaro & Zepbound can easily pull through in 2H24 and make up for any 1H24 shortfalls." For the week ended April 19, combined prescriptions of Mounjaro and Zepbound rose 63% year over year, according to IQVIA. Wells Fargo Mohit Bansal said he expects investors to look past any Trulicity shortfalls as the focus is firmily on Zepbound and Mounjaro for Lilly's future growth.

Persons: Eli Lilly, Eli, James Shin, Lilly, Shin, David Risinger, Zepbound, Wells, Bansal, Jo Walton, Walton, Lilly's, Tirzepatide, Deutsche Bank's Shin, — CNBC's Michael Bloom Organizations: Drug Administration, Deutsche Bank, IMS, UBS, Research, Deutsche, FDA Locations: 2H24, U.S

☆ Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
▼ + stars: | 2023-12-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. "We expect this environment to continue but look forward to the prospect of lower interest rates in 2024." When that happens, Canaccord Genuity said to expect a "strong rally across the biotech sector rewarding innovative, but riskier assets." Analysts have said the rich price reflects the opportunity for ImmunoGen's Elahere cancer treatment , which has quickly established itself as the standard of care for types of ovarian cancer. 'Oversold and cheap' In a research note Friday, Jefferies analyst Michael Yee said "a significant short squeeze" was helping biotech stocks in the fourth quarter.

Persons: Dan Lyons, Janus Henderson, John Newman, Canaccord Genuity, Janus, Lyons, Bristol Myers Squibb, Karuna, AstraZeneca, Eli Lilly, AbbVie, Jonathan Miller, Miller, bode, Jonathan Krinsky, Krinsky, BTIG's, Jefferies, Michael Yee, Yee, NASH, Madrigal, we're, David Risinger, — CNBC's Michael Bloom Organizations: Drug, Federal, Bristol Myers, Karuna Therapeutics, CART, Bristol Myers Squibb, Cerevel Therapeutics, Securities and Exchange Commission, pharma, P Biotech, Nasdaq Biotech, Apogee Therapeutics, Madrigal Pharmaceuticals, Madrigal, resmetirom, Vertex Pharmaceuticals, Leerink Partners Locations: ImmunoGen

A sign is pictured outside an Eli Lilly and Company pharmaceutical manufacturing plant at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Incretins are peptide-based drugs such as Mounjaro that mimic gut hormones to suppress appetite and stimulate insulin secretion. Lilly said it had announced investments of more than $11 billion in global manufacturing in the past three years. Major production sites that Lilly runs outside of its U.S. home market are in Ireland, France, Spain, Italy and China. The new Alzey site will employ up to 1,000 highly skilled workers such as engineers, technicians and scientists, said Lilly.

Persons: Eli Lilly, Mike Segar, Lilly, Karl Lauterbach, Lauterbach, generics, Patrick Wingrove, Matthias Williams, Jason Neely, David Evans Organizations: Company, REUTERS, Rights, Reuters, U.S ., Novo Nordisk, European Union, pharma, The U.S ., Thomson Locations: Branchburg , New Jersey, Germany, Alzey, U.S, United States, Danish, Berlin, Fegersheim, France, European, Indiana , North Carolina, Limerick, Ireland, Spain, Italy, China, The U.S

☆ Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here's why, analyst says
▼ + stars: | 2023-11-10 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? LLY YTD mountain Eli Lilly shares since the start of the year. According to Shin, Lilly deserves a premium to Novo Nordisk because its portfolio is more diverse and it has less exposure to insulin. NVO YTD mountain Novo Nordisk shares year to date In the coming weeks, Lilly will start rolling out Zepbound to patients. Novo Nordisk is scheduled to release the full results of its Select cardiovascular trial at the American Heart Association conference.

Persons: Eli Lilly, James Shin, Shin, Lilly, We're, Lilly's, Zepbound, Wegovy, Chris Schott, Karsten Munk Knudsen, Novo, Schott, AstraZeneca, Eccogene, David Ricks, — CNBC's Michael Bloom Organizations: Novo Nordisk, Deutsche Bank, Biotech, Pharma, Centers for Disease Control, Novo, CNBC, American Heart Association Locations: U.S, GLP, Novo, Denmarkt

☆ Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly on Thursday said supply of its blockbuster diabetes drug Mounjaro has improved in the U.S. after months of widespread shortages. During an earnings call Thursday, Eli Lilly executives said the company experienced tight supply for Mounjaro throughout most of the third quarter. But U.S. product shipments of Mounjaro have recently increased, and inventory levels at U.S. drug wholesalers have improved, according to Eli Lilly CFO Anat Ashkenazi. Eli Lilly has also invested more than $3 billion to build two new manufacturing sites in its home state of Indiana. Eli Lilly's main rival in the weight loss drug space, Novo Nordisk , is still navigating its own supply constraints of diabetes drug Ozempic and obesity treatment Wegovy.

Persons: Eli Lilly, Mounjaro, Eli Lilly's, Anat Ashkenazi, Ashkenazi, David Ricks, Ricks, we're, Wegovy, Eli Lilly's Mounjaro Organizations: Novo Nordisk, Pharmacy, Food, Pfizer Locations: Provo , Utah, U.S, North Carolina, Indiana, Novo

☆ Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers
▼ + stars: | 2023-10-23 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

Most analysts predict the market for new weight loss drugs like Wegovy and Mounjaro will be enormous, but estimates vary for its exact size depending on who you ask. On Monday, Citi raised its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. Last month, the firm made a case for there being a $150 billion to $200 billion opportunity for these drugs. At the moment, private insurance coverage isn't a guarantee for those seeking weight loss treatment, and the federal Medicare program doesn't cover weight loss drugs at all. Lilly expects the Food and Drug Administration to approve this drug to treat obesity by the end of this year.

Persons: Seamus, Fernandez, Andrew Baum, Goldman Sachs, Chris Shibutani, Shibutani, Eli Lilly, Lilly Organizations: Monday, Citi, Wegovy, Food and Drug Administration Locations: GLP

☆ These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
▼ + stars: | 2023-10-22 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. "This is a major shortcoming in terms of not just quality of life for the patients who have to lose lean muscle mass, but there's actually room to improve on the weight loss and there [are] other metabolic benefits to improving your lean muscle mass ... [including] you might have better durability of weight loss." The drug is being tested in a phase 2b study alongside semaglutide to protect against loss of muscle mass. Until then, patients will need to watch what they eat and focus on exercise just as they would on any other weight loss regimen. When that occurs, muscle loss will be an even bigger issue than it is now.

Persons: Piper Sandler, Allison Bratzel, there's, Bratzel, Versanis, Eli Lilly, Eli Lilly's Mounjaro, they're, Lydia Alexander, Alexander, Sandler's Bratzel, incretins, Biohaven, Nestle, Ulf Mark Schneider, Jeff Jonas, Jonas, Stephens, Jim Salera, Atkins, Morgan Stanley, — CNBC's Michael Bloom Organizations: Wall, Nordisk's Ozempic, Obesity Medicine Association, Bristol Myers Squibb, Nestle, Gabelli, Quest, Foods Locations: Swiss

☆ Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
▼ + stars: | 2023-09-16 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Fernandez sees a total addressable market of $140 billion to support patients with obesity. He expects there is a potential for GLP-1 drugs to become as common and widely used, much like statins are used to lower cholesterol. Morgan Stanley's Flynn estimates a 30% share of the diabetes market would generate $109 billion on a worldwide basis for GLP-1 drugs. Layer in a 15% to 30% share of the obesity market and that equates to worldwide sales of $97.4 billion to $194.8 billion. Guggenheim's estimates also assume that oral GLP-1 drugs that are currently in development are able to come to market a few years from now.

Persons: Seamus Fernandez, Fernandez, Lilly, Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's Mounjaro, Insulet, Canaccord, William Plovanic, Plovanic, It's, Morgan Stanley's Flynn, Flynn, Novo, Michael Bloom Organizations: Wall, Novo, American Heart Association, Food and Drug Administration, Novo Nordisk, Iqvia, Disease Control Locations: GLP

☆ Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion
▼ + stars: | 2023-07-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Eli Lilly on Friday said it will acquire Versanis, a privately held obesity drug maker, for up to $1.93 billion to boost the pharmaceutical giant's weight loss treatment portfolio. Eli Lilly agreed to pay Versanis shareholders in cash, which will consist of an upfront payment and potentially subsequent payments if Versanis achieves certain "development and sales milestones." Oakland, California-based Versanis, which was founded in 2021 by biotech investment firm Aditum Bio, has one experimental drug for obesity and potentially other conditions. Analysts project that the global weight loss drug market could be worth $100 billion by around 2030. Versanis' drug, bimagrumab, binds directly to certain cells in the body to reduce fat mass.

Persons: Eli Lilly, Versanis, Aditum, Eli Lilly's Organizations: Novo Nordisk, Novo Nordisk's Wegovy Locations: Oakland , California, Ozempic, U.S, Indianapolis

July 14 (Reuters) - Eli Lilly and Co (LLY.N) said on Friday it will buy privately held Versanis for potentially up to $1.93 billion to strengthen its position in the fast-growing market for weight-loss treatments. Shares of Eli Lilly rose 3% after the deal that gives it access to an experimental obesity drug being tested along with rival Novo Nordisk's (NOVOb.CO) weight-loss treatment in a mid-stage study. Analysts expect the market for weight-loss drugs to reach up to $100 billion within a decade, with early movers such as Eli Lilly and Novo Nordisk grabbing a large chunk of the market. "One of the key concerns with weight loss medications is the loss of lean mass. The goal is to lose more fat vs. muscle, but with any weight loss program calorie restriction could impact both," said BMO Capital Markets analyst Evan Seigerman.

Persons: Eli Lilly, Novo, Evan Seigerman, Lilly, Sriparna Roy, Arun Koyyur Organizations: Novo Nordisk's, Novo Nordisk, Capital, Novartis, Thomson Locations: Swiss, Bengaluru

☆ Analysis: Weight loss drug candidates multiply, spurring hopes of better outcomes, lower costs
▼ + stars: | 2023-06-27 | by ( Deena Beasley | ) www.reuters.com time to read: +5 min

More than 40% of Americans are obese, according to the U.S. Centers for Disease Control and Prevention, and demand is strong for treatments to reduce body weight as well as maintain weight loss. The company said it would continue to develop its twice-daily weight loss drug candidate. Structure Therapeutics (GPCR.O) is developing oral obesity drugs that it says are simpler to manufacture than the current injectables. "We define weight loss quality as the percentage of weight loss attributed to fat loss," said Versanis Chief Scientific Officer Lloyd Klickstein. "With diets, bariatric surgery, incretin drugs or other weight loss drugs, two-thirds to three-quarters of the weight loss is fat, but one-quarter to one-third is lean."

Persons: Robert Gabbay, Eli Lilly, Lilly's, Wegovy, Mico Guevarra, Lilly, Jeff Emmick, Ray Stevens, Boehringer Ingelheim, Versanis, Lloyd Klickstein, Chaguturu, Deena Beasley, Michele Gershberg, Jamie Freed Organizations: DIEGO, Novo Nordisk's, American Diabetes Association, Novo, U.S . Centers for Disease Control, ADA, Pfizer, Therapeutics, Zealand Pharma, Novartis, CVS Health, Aetna, Thomson Locations: San Diego, GLP

☆ Lilly experimental 'triple G' obesity drug leads to 24.2% weight loss in trial
▼ + stars: | 2023-06-26 | by ( Deena Beasley | ) www.reuters.com time to read: +2 min

Companies Eli Lilly and Co FollowJune 26 (Reuters) - Eli Lilly (LLY.N) on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs. Lilly's Mounjaro, which is awaiting U.S. regulatory approval for treatment of obesity, targets GLP-1 as well as a second obesity-related hormone called GIP. Retatrutide targets GLP-1, GIP and the body's receptors for a third hormone, glucagon. Given the three targets, Lilly has nicknamed the drug triple G.The company reported last year that a trial of Mounjaro in people who were obese or overweight found it led to weight loss of 22.5% after 72 weeks. Lilly is conducting longer-duration phase 3 trials of retatrutide to see if weight loss might be further improved.

Persons: Eli Lilly, Lilly's, Lilly, ” Dan Skovronsky, Deena Beasley, Deepa Babington, Cynthia Osterman Organizations: American Diabetes Association, New England, of Medicine, Thomson Locations: San Diego

Search resuls for: "incretins"

13 mentions found